The extensive REMS assessment for ProStrakan's Abstral details the data collection burden sponsors face as they institute restricted distribution programs and FDA asks more questions about the burden placed on the health care system as well as the effects on patient access to medications.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.
Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.
China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.
